

CARB-X Portfolio: Accelerating Innovation in Antibacterial Drug Development

Tina Guina, PhD Program Manager, BARDA/ASPR/HHS

FDA Workshop: Advancing Animal Models for Antibacterial Drug Development March 5, 2020

UNCLASSIFIED

CARB-X

Combating Antibiotic Resistant Bacteria

A global non-profit partnership accelerating science to fight drug resistant bacteria. CARB-X supports R&D from around the world to address the most serious drug-resistant bacterial infections.



CARB-X Funds Candidates that Address Serious Bacterial Threats

Portfolio includes

- Traditional and non-traditional therapeutics
- Preventives such as vaccines, microbiome, and antibodies
- Rapid diagnostics for pathogen ID/AST

Projects must target specific bacteria on the Antibiotic Resistance Threats list issued by the CDC in 2013, the Priority Bacterial Pathogens list published by WHO in 2017, or included in the Vaccines to Tackle Drug Resistant Infections: An Evaluation of R&D Opportunities joint report from The Wellcome Trust and Boston Consulting Group.





In Addition to Funding, CARB-X Provides Scientific, Regulatory and Business Expertise and Support

Support

- Company Support Teams and accelerators tailored to each program's needs
- Specialized know-how in antibacterial drug development, diagnostics, vaccines, business and legal strategy, regulatory affairs, and other areas essential to product development
- No cost to product developers
- Streamlined access to NIAID preclinical services
- Benefits of CARB-X ecosystem








9 world-class accelerators in 5 countries supporting the development of new antibiotics and other life-saving products to fight drug-resistant bacteria



CARB-X Program Progress Since Initiation*





CARB-X Direct-Acting Therapeutics, Target Pathogens and Stages of Development*

Cell-wall synthesis	DNA synthesis	Protein synthesis	Fatty-acid biosynthesis		
PBPi – next-generation Iterum Ph1 ESKAPE	<u>NBTI</u> Bugworks LO→PC ESKAPE Idorsia PC ESKAPE	<u>30S – next-generation</u> Tetraphase Ph1 ESKAPE	Debiopharm LO→PC Ng Debiopharm LO ESKAPE		
Novel PBPi Entasis LO ESKAPE Venatorx HtL Ng		50S- next-generationZikani LO→PCESKAPEtRNA synthetase I			
BL/BLI Entasis Ph1 ESKAPE	RNA synthesis	Oxford D.D. HtL ESKAPE	Other		
LpxC			Summit PC Ng		
ForgeUTI LO→PCESKAPEForgeRTI LOESKAPE	*CARB-X portfolio as of 2/1/2020				
OMPTA Oppilotech HtL ESKAPE	Staphylococc	socomial virulent drug-resistant patho sus aureus, Klebsiella pneumoniae, A s aeruginosa, and Enterobacter spp.	•		

HtL, Hit-to-Lead. LO, Lead Optimization. PC, preclinical, IND-enabling, Ph1, Phase 1.



Polyphor PC

ESKAPE

CARB-X 'Non-traditional' Therapeutics, Target Pathogens and Stages of Development*

Anti-Virulence		Phage/Lysins		Microbi	Microbiome	
Antabio (elastase i) LO→PC Microbiotix (T3SSi) PC Bioversys (AgrAi) LO Trellis (biofilm) PC	ESKAPE ESKAPE ESKAPE ESKAPE	Contrafect HtL→LO	ESKAPE	Vedanta Ph1 Seres PC Vedanta PC	Cd ESKAP ESKAP	
		Membrane Disru	ption	Othe	r	
Potentiators		Peptides		Bravos PC	ESKAF	
Spero Ph1 Taxis HtL	ESKAPE ESKAPE	Amicrobe (topical) PC Contrafect (amurin) HtL MicuRx (polymyxin) PC	ESKAPE ESKAPE ESKAPE	Centauri LO Procarta LO Techulon HtL	ESKAI ESKAI ESKAI	

Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. HtL, Hit-to-Lead. LO, Lead Optimization. PC, preclinical, IND-enabling, Ph1, Phase 1.

*CARB-X portfolio as of 2/1/2020

ASPR

CARB-X R&D Opportunities in Utilization of Animal Models and PK/PD to Support Clinical Development

We aim to establish best practices and guide developers in utilizing animal model data to mitigate development risk and support product clinical pharmacology dossier. For example:

- HABP/VABP, MDR pathogen studies
- Narrow spectrum indications, most candidates are 'nontraditionals'
 - ✓ Pseudomonas
 - ✓ Acinetobacter
 - ✓ MRSA
 - ✓ Neisseria gonorrhoeae
 - ✓ Clostridium difficile
 - ✓ Enterobacter
- Anti-virulence candidates regulatory pathway??
- Nephrotoxicity models and translation to clinic, etc.



Efficacy Models Considerations for CARB-X Portfolio

Product Candidate Class	Pathogens & Indications	Questions on Animal Models
Narrow spectrum direct-acting agents	Acinetobacter Pseudomonas HABP/VABP	Best models to translate in vitro activity?
Narrow spectrum indirect-acting, nontraditional agents	Acinetobacter Pseudomonas Staphylococcus HABP/VABP	Best models to translate in vitro activity? Are the best predictive models the same as those used for direct-acting agents?
Peptides and other nontraditional agents	ESKAPE broad spectrum HABP/VABP	If in vitro activity is higher for Pseudomonas and/or Acinetobacter, what is the best demonstration of efficacy to justify a narrow clinical focus?
Direct acting agents	Neisseria gonorrhoeae	Best models to translate in vitro activity?



BARDA Nonclinical Development Network

- Facilitates nonclinical model development and/or supportive reagents and assays for regulatory acceptance of BARDA MCMs and evaluates potential MCM candidates prior to BARDA investment
- Network partnerships with 19 nonclinical laboratories to support:
 - Biological Nonclinical Program support of antibacterial studies
 - Development and refinement of nonclinical infection models for evaluation of antimicrobial agents
 - Porcine model of VABP caused by Pseudomonas aeruginosa
 - Hamster model of Clostridioides difficile infection
 - Multiple models of infection with Tier 1 bacterial select agents
 - Chemical Nonclinical Program
 - Rad/Nuc Nonclinical Program

Supported 40+ programs across BARDA divisions. Contributed to licensure or approval of 6 MCMs under the Animal Rule.





Acknowledgments

CARB-X R&D Team

Erin Duffy Richard Alm Ed Buurman Su Chiang Nadia Cohen Maria Uria-Nickelsen Betsy Wonderly Trainor

CARB-X Core

Kevin Outterson Karen Gallant Richard Lawson Diane MacDonald and Colleagues...



CARB-X Ecosystem Partners Product Sponsors Funding Partners Accelerators Scientific Advisory Board

<u>NIAID</u>

Ann Eakin Anita Sheoran Erica Raterman Erin Zeituni **BARDA**

Mark Albrecht Adam Clark Alan Goldberg Gary Horwith **Christopher Houchens** Saddef Hag **Claiborne Hughes** Marina Kozak Gilbert Marks Tyler Merkeley Andrew Phipps Anna O'Rourke Oxana Selivanova Robert Walker Daniel Wolfe



How to Contact BARDA





www.usajobs.gov Join the team!

